John Valliant - Feb 1, 2022 Form 4 Insider Report for Fusion Pharmaceuticals Inc. (FUSN)

Role
Chief Executive Officer, Director
Signature
/s/Maria Stahl as Attorney-in-Fact for John Valliant
Stock symbol
FUSN
Transactions as of
Feb 1, 2022
Transactions value $
$0
Form type
4
Date filed
2/3/2022, 06:40 PM
Next filing
Feb 17, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FUSN Stock Option (Right to Buy) Award $0 +407K $0.00 407K Feb 1, 2022 Common Stock 407K $7.70 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option vests in 48 equal monthly installments beginning on March 1, 2022.